Vagina administration mifepristone prepn and its composition and prepn process

Abstract

The vagina administrated mifepristone preparation for birth control and health reproduction consists of mifepristone or nanometer mifepristone liposome particle as main component, excipient, osmosis promoter, pH regulator, preservative, surfactant, solvent, water and other pharmaceutically acceptable components, and may be prepared into gel, film or other preparation forms. The vagina administrated mifepristone preparation is absorbed through vagina mucous membrane into blood circulation, and has high bioavailability, lowered dosage, less toxic side effect and less stimulation.

Description

[0001] Field:

[0002] The invention belongs to the technical field of medicine, and relates to a preparation for vaginal administration of mifepristone for family planning and reproductive health, as well as its composition and preparation method. Background technique:

[0003] Mifepristone (Mifepristone) was successfully developed in 1982 by the French company Roussel-Uclaf (original code Ru-486), which is an orally absorbed drug through the gastrointestinal tract with anti-progestin and anti-glucocorticoid activity. Mifepristone was initially used clinically as a drug for terminating early pregnancy, and its effectiveness and safety have been confirmed. With the deepening of its understanding, mifepristone is now widely used in family planning and reproductive health, such as: termination of (early, middle, and late) pregnancy, emergency contraception, and treatment of some gynecological diseases, such as: uterus Fibroids, abnormal uterine bleeding, endometriosis, endometr...